Ajovy Euroopan unioni - suomi - EMA (European Medicines Agency)

ajovy

teva gmbh - fremanezumab - migreenihäiriöt - calcitonin gene-related peptide (cgrp) antagonists - ajovy on tarkoitettu käytettäväksi migreenin ennaltaehkäisyyn aikuisilla, joilla on vähintään 4 migreeni päivää kuukaudessa.

Tambocor Retard 100 mg depotkapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

tambocor retard 100 mg depotkapseli, kova

viatris oy - flecainide acetate - depotkapseli, kova - 100 mg - flekainidi

Tambocor Retard 200 mg depotkapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

tambocor retard 200 mg depotkapseli, kova

viatris oy - flecainide acetate - depotkapseli, kova - 200 mg - flekainidi

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Emla 25 mg/g + 25 mg/g emulsiovoide Suomi - suomi - Fimea (Suomen lääkevirasto)

emla 25 mg/g + 25 mg/g emulsiovoide

aspen pharma trading limited - prilocaine, lidocaine - emulsiovoide - 25 mg/g + 25 mg/g - yhdistelmävalmisteet

Tapin 25 mg/g + 25 mg/g emulsiovoide Suomi - suomi - Fimea (Suomen lääkevirasto)

tapin 25 mg/g + 25 mg/g emulsiovoide

orifarm generics a/s - lidocaine, prilocaine - emulsiovoide - 25 mg/g + 25 mg/g - yhdistelmävalmisteet

Krystexxa Euroopan unioni - suomi - EMA (European Medicines Agency)

krystexxa

crealta pharmaceuticals ireland limited - pegloticase - kihti - antigout-valmisteet - krystexxa on tarkoitettu kohtelu vaikea heikentävä krooninen tophaceous kihti aikuisilla, jotka voi olla erosive osallistuminen ja jotka eivät ole normalisoida seerumin virtsahappo ksantiiniguaniinifosforibosyylitransferaasin monoamiinioksidaasin estäjiä suurimmalla lääketieteellisesti sopiva annos tai jolle nämä lääkkeet ovat vasta.

Emla lääkelaastari Suomi - suomi - Fimea (Suomen lääkevirasto)

emla lääkelaastari

aspen pharma trading limited - prilocaine, lidocaine - lääkelaastari - yhdistelmävalmisteet

Tapin 25 mg / 25 mg lääkelaastari Suomi - suomi - Fimea (Suomen lääkevirasto)

tapin 25 mg / 25 mg lääkelaastari

orifarm generics a/s - lidocaine, prilocaine - lääkelaastari - 25 mg / 25 mg - yhdistelmävalmisteet

Emgality Euroopan unioni - suomi - EMA (European Medicines Agency)

emgality

eli lilly nederland b.v. - galcanezumab - migreenihäiriöt - analgesics, galcanezumab - emgality on tarkoitettu käytettäväksi migreenin ennaltaehkäisyyn aikuisilla, joilla on vähintään 4 migreeni päivää kuukaudessa.